GLEEVEC Trademark

Trademark Overview

On Wednesday, April 4, 2001, a trademark application was filed for GLEEVEC with the United States Patent and Trademark Office. The USPTO has given the GLEEVEC trademark a serial number of 78056665. The federal status of this trademark filing is REGISTERED AND RENEWED as of Wednesday, June 21, 2023. This trademark is owned by Novartis AG. The GLEEVEC trademark is filed in the Pharmaceutical Products category with the following description:

pharmaceutical preparations, for use in the field of oncology, namely, for the treatment of cancer
gleevec

General Information

Serial Number78056665
Word MarkGLEEVEC
Filing DateWednesday, April 4, 2001
Status800 - REGISTERED AND RENEWED
Status DateWednesday, June 21, 2023
Registration Number2675047
Registration DateTuesday, January 14, 2003
Mark Drawing1000 - Typeset: Word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, October 22, 2002

Trademark Statements

Goods and Servicespharmaceutical preparations, for use in the field of oncology, namely, for the treatment of cancer

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, April 9, 2001
Primary Code005
First Use Anywhere DateFriday, May 11, 2001
First Use In Commerce DateFriday, May 11, 2001

Trademark Owner History

Party NameNovartis AG
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressBasel 4002
CH
Party NameNovartis AG
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressBasel
CH
Party NameNovartis AG
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressBasel
CH

Trademark Events

Event DateEvent Description
Wednesday, June 21, 2023NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
Wednesday, June 21, 2023REGISTERED AND RENEWED (SECOND RENEWAL - 10 YRS)
Wednesday, June 21, 2023REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
Thursday, June 15, 2023CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Friday, November 18, 2022TEAS SECTION 8 & 9 RECEIVED
Friday, January 14, 2022COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Saturday, December 8, 2012NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
Saturday, December 8, 2012REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
Saturday, December 8, 2012REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
Saturday, December 8, 2012CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Monday, November 12, 2012TEAS SECTION 8 & 9 RECEIVED
Thursday, June 18, 2009TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, February 20, 2008REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Tuesday, February 19, 2008ASSIGNED TO PARALEGAL
Thursday, February 14, 2008TEAS SECTION 8 & 15 RECEIVED
Wednesday, January 16, 2008CASE FILE IN TICRS
Sunday, December 19, 2004TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, December 6, 2004PAPER RECEIVED
Tuesday, January 14, 2003REGISTERED-PRINCIPAL REGISTER
Tuesday, October 22, 2002PUBLISHED FOR OPPOSITION
Wednesday, October 2, 2002NOTICE OF PUBLICATION
Wednesday, August 7, 2002APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, August 7, 2002USE AMENDMENT ACCEPTED
Thursday, June 6, 2002AMENDMENT TO USE PROCESSING COMPLETE
Wednesday, February 13, 2002USE AMENDMENT FILED
Friday, February 15, 2002CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, August 13, 2001NON-FINAL ACTION MAILED
Thursday, August 9, 2001ASSIGNED TO EXAMINER

Related Keywords

gleevec treatment cancer namely oncology preparations field pharmaceutical